Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.85 |
| ▸ | ALPI | P09923 | 1/20 | 0.85 |
| ▸ | PKM | P14618 | 1/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.85 |
| ▸ | XIAP | P98170 | 1/20 | 0.85 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.64 |
| ▸ | LAP3 | P28838 | 3/20 | 0.61 |
| ▸ | ANPEP | P15144 | 1/20 | 0.61 |
| ▸ | PTPRC | P08575 | 1/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.61 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.61 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.61 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL4958176 | 1.00 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL7645387 | 0.94 | SLC7A5 (0.81) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL7645389 | 0.94 | SLC7A5 (0.81) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL8610205 | 0.93 | SLC7A5 (0.79) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL8610206 | 0.93 | SLC7A5 (0.79) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL23159186 | 0.92 | SLC7A5 (1.00) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL16398197 | 0.92 | SLC7A5 (1.00) | SLC7A5ALPIPKMPTGS1XIAP | |
| D-Phenylalanine SCHEMBL837632 | 0.92 | SLC7A5 (1.00) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL8118 | 0.92 | SLC7A5 (1.00) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL43671 | 0.92 | SLC7A5 (1.00) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105722392-B | Compositions of non-nucleoside reverse transcriptase inhibitors | 默沙东公司 | 2019-07-23 | — | — | CN | disclosed |
| WO-2015122868-A1 | APPLICATION OF GREEN TECHNOLOGY TECHNIQUES TO CONSTRUCT A BIODEGRADABLE ARTIFICIAL REEF | MANNING THOMAS (US) | 2015-08-20 | — | — | WO | disclosed |
| US-7329644-B2 | Preparation and use of cyclic and branched peptides and their labelled derivatives as therapeutic agents, cholecystokinin agonists or antagonists, and diagnostic agents to identify and locate tumours | BRACCO IMAGING S.P.A. (IT) | 2008-02-12 | — | — | US | disclosed |
| EP-1390405-B1 | PREPARATION OF CHOLECYSTOKININ AGONISTS AND ANTAGONISTS AND THEIR THERAPEUTIC AND DIAGNOSTIC USE | BRACCO IMAGING SPA (IT) | 2007-01-24 | — | — | EP | disclosed |
| US-20040254339-A1 | Preparation and use of cyclic and branched peptides and their labelled derivatives as therapeutic agents, cholecystokinin agonists or antagonists, and diagnostic agents to identify and locate tumours | BRACCO IMAGING S.P.A. (IT) | 2004-12-16 | — | — | US | disclosed |
| EP-1390405-A2 | PREPARATION OF CHOLECYSTOKININ AGONISTS AND ANTAGONISTS AND THEIR THERAPEUTIC AND DIAGNOSTIC USE | Bracco Imaging S.p.A. (IT) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002094873-A2 | PREPARATION OF CHOLECYSTOKININ AGONISTS AND ANTAGONISTS, AND THEIR THERAPEUTIC AND DIAGNOSTIC USE | BRACCO IMAGING S.P.A. (IT) | 2002-11-28 | — | — | WO | disclosed |
| US-5723576-A | POLYPEPTIDES FOR ENZYME INHIBITORS AND HIRUNDIN | DEVELOPMENT BIOTECHNOLOGICAL PROCESSES S.N.C. (IT) | 1998-03-03 | — | — | US | disclosed |
| EP-0804470-A1 | THROMBIN INHIBITORS, THE PREPARATION THEREOF AND THE USE THEREOF FOR THERAPEUTICAL, PROPHYLACTIC AND DIAGNOSTIC APPLICATIONS | DEVELOPMENT BIOTECHNOLOGICAL PROCESSES S.N.C. DI PELLICCIA MARIA TERESA (IT) | 1997-11-05 | — | — | EP | disclosed |
| EP-0376230-B1 | Preparation and isolation of mineral acid salt of an amino methyl ester | MITSUI TOATSU CHEMICALS (JP) | 1994-11-23 | — | — | EP | disclosed |
| WO-1994024156-A1 | THROMBIN INHIBITORS, THE PREPARATION THEREOF AND THE USE THEREOF FOR THERAPEUTICAL, PROPHYLACTIC AND DIAGNOSTIC APPLICATIONS | DEVELOPMENT BIOTECHNOLOGICAL PROCESSES S.N.C. DI PELLICCIA MARIA TERESA (IT) | 1994-10-27 | — | — | WO | disclosed |
| US-5113009-A | PREPARATION AND ISOLATION OF MINERAL ACID SALT OF AN AMINO ACID METHYL ESTER | MITSUI TOATSU CHEMICALS, INCORPORATED | 1992-05-12 | — | — | US | disclosed |
| EP-0376230-A2 | Preparation and isolation of mineral acid salt of an amino methyl ester | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254339-A1 | Preparation and use of cyclic and branched peptides and their labelled derivatives as therapeutic agents, cholecystokinin agonists or antagonists, and diagnostic agents to identify and locate tumours | CCKBR, CCKAR, GRPR | SLC7A5 182/4885ALPI 1381/4885PKM 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.